Improvement of tardive dyskinesia following amisulpride treatment

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 30, Issue 4, 2006, Pages 748-750

  Peritogiannis, Vaios ^a   Tsouli, Sofia ^a   Zafiris, Spiros ^a   Pappas, Dimitrios ^a   Mavreas, Venetsanos ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Amisulpride; Clozapine; Tardive dyskinesia

Indexed keywords

AMISULPRIDE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR BLOCKING AGENT; RISPERIDONE;

ADULT; ARTICLE; CASE REPORT; DISEASE COURSE; DRUG EFFECT; FEMALE; HUMAN; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; DYSKINESIAS; FEMALE; HUMANS; MIDDLE AGED; SCHIZOPHRENIA, PARANOID; SULPIRIDE;

EID: 33646101684     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2006.01.022     Document Type: Article

References (28)

1. Alptekin K., and Kivircik B.B. Quetiapine-induced improvement of tardive dyskinesia in three patients with schizophrenia. Int Clin Psychopharmacol 17 (2002) 263-264
2. Beasley C.M., Dellva M.A., Tamura R.N., Morgenstern H., Glazer W.M., Ferguson K., et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 174 (1999) 23-30
3. 123I]epidepride SPET study of amisulpride-treated patients. Am J Psychiatry 160 (2003) 1413-1420
4. Bressan R.A., Jones H.M., and Pilowsky L.S. Atypical antipsychotic drugs and tardive dyskinesia: relevance of D2 receptor affinity. J Psychopharmacol 18 (2004) 124-127
5. Casey D.E. Tardive dyskinesia: pathophysiology. In: Bloom F.E., and Kupfer D.J. (Eds). Psychopharmacology: the fourth generation of progress (1995), Raven Press, New York 1497-1502
6. Casey D.E. Effects of clozapine therapy in schizophrenic individuals at risk for tardive dyskinesia. J Clin Psychiatry 59 Suppl. 3 (1998) 31-37
7. Casey D.E. Tardive dyskinesia and atypical antipsychotic drugs. Schizophr Res 35 (1999) 61-66 [Suppl.]
8. Chen J.Y., Bai Y.M., Pynk L.Y., and Lin C.C. Risperidone for tardive dyskinesia (letter). Am J Psychiatry 158 (2001) 1931-1932
9. Correll C.U., Leucht S., and Kane J.M. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 161 (2004) 414-425
10. Coulouvrat C., and Dondey-Nouvel L. Safety of amisulpride (Solian): a review of 11 clinical studies. Int Clin Psychopharmacol 14 (1999) 209-218
11. Davis J.M., Chen N., and Glick I.D. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60 (2003) 553-564
12. Gardos G., and Cole J.O. The treatment of tardive dyskinesias. In: Bloom F.E., and Kupfer D.J. (Eds). Psychopharmacology: the fourth generation of progress (1995), Raven Press, New York 1503-1511
13. Gupta S., Mosnik D., Black D.W., Berry S., and Masand P.S. Tardive dyskinesia: review of treatments past, present, and future. Ann Clin Psychiatry 11 (1999) 257-266
14. Hong K.S., Cheong S.S., Woo J.M., and Kim E. Risperidone-induced tardive dyskinesia (letter). Am J Psychiatry 156 (1999) 1290
15. Kane J.M. Tardive dyskinesia: epidemiological and clinical presentation. In: Bloom F.E., and Kupfer D.J. (Eds). Psychopharmacology: the fourth generation of progress (1995), Raven Press, New York 1485-1495
16. Kapur S., and Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 158 (2001) 360-369
17. Leucht S., Pitschel-Walz G., Engel R.R., and Kissling W. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 159 (2002) 180-190
18. Lieberman J.A., Saltz B.L., Johns C.A., Pollack S., Borenstein M., and Kane J. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 158 (1991) 503-510
19. Littrell K.H., Johnson C.G., Littrell S., and Peabody C.D. Marked reduction of tardive dyskinesia with olanzapine. Arch Gen Psychiatry 55 (1998) 279-280
20. Llorca P.M., Chereau I., Bayle F.J., and Lancon C. Tardive dyskinesias and antipsychotics: a review. Eur Psychiatry 17 (2002) 129-138
21. Moller H.J. Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27 (2003) 1101-1111
22. Schoemaker H., Claustre Y., Fage D., Rouquier L., Chergui K., and Curet O. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limpic selectivity. J Pharmacol Exp Ther 280 (1997) 83-97
23. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 47 (2002) 27-38
24. Speller J.C., Barnes T.R., Curson D.A., Pantelis C., and Alberts J.L. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms: amisulpride v. haloperidol. Br J Psychiatry 171 (1997) 564-568
25. Wirshing W.C. Movement disorders associated with neuroleptic treatment. J Clin Psychiatry 62 Suppl. 21 (2001) 15-18
26. Woerner M.G., Sheitman B.B., Lieberman J.A., and Kane J.M. Tardive dyskinesia induced by risperidone?. Am J Psychiatry 153 (1996) 843
27. Xiberas X., Martinot J.L., Mallet L., Artiges E., Canal M., Loc'h C., et al. In vivo extrastratial and stratial D2 dopamine receptor blockage by amisulpride in schizophrenia. J Clin Psychopharmacol 21 (2001) 207-214
28. Xiberas X., Martinot J.L., Mallet L., Artiges E., Loc'h C., Maziere B., et al. Extrastratial and stratial D2 dopamine receptor blockage with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br J Psychiatry 179 (2001) 503-508